Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Acceleron Pharma Inc.    XLRN

ACCELERON PHARMA INC.

(XLRN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Acceleron Pharma : , Bristol-Myers Shares Up After New FDA Nod for Reblozyl

share with twitter share with LinkedIn share with facebook
share via e-mail
04/06/2020 | 10:32am EDT

By Colin Kellaher

 

Acceleron Pharma Inc. shares rose nearly 6% on Monday after the U.S. Food and Drug Administration approved the use of the anemia drug Reblozyl in adults with lower-risk myelodysplastic syndromes.

The Cambridge, Mass., biopharmaceutical company is developing Reblozyl with Bristol-Myers Squibb Co.'s Celgene under a collaboration they formed in 2011. Bristol-Myers shares also moved higher.

On Friday, the companies said the FDA approval marks the second indication for Reblozyl and the first new treatment option in more than a decade for patients with myelodysplastic syndromes who require red-blood-cell transfusions and have failed an erythropoiesis stimulating agent.

Acceleron shares were recently up 5.9% to $85.51, while shares of Bristol-Myers rose 3.9% to $57.69.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
ACCELERON PHARMA INC. -0.19% 98.83 Delayed Quote.86.40%
BRISTOL-MYERS SQUIBB COMPANY -0.15% 59.72 Delayed Quote.-6.96%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ACCELERON PHARMA INC.
05/21ACCELERON PHARMA : Announces Presentations on REBLOZYL at the 2020 American Soci..
AQ
05/20ACCELERON PHARMA : Announces Presentations on REBLOZYL® (luspatercept-aamt) at t..
BU
05/19ACCELERON PHARMA : Announces Oral Presentation of PULSAR Phase 2 Trial Results i..
BU
05/13ACCELERON PHARMA : Announces Publication in Science Translational Medicine Descr..
BU
05/11ACCELERON : 1Q Earnings Snapshot
AQ
05/11ACCELERON PHARMA : Management's Discussion and Analysis of Financial Condition a..
AQ
05/11ACCELERON PHARMA INC : Results of Operations and Financial Condition, Financial ..
AQ
05/11ACCELERON PHARMA : Reports First Quarter 2020 Operating and Financial Results
BU
05/05ACCELERON PHARMA INC : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
05/05ACCELERON PHARMA : to Webcast First Quarter 2020 Operating and Financial Results..
BU
More news
Financials (USD)
Sales 2020 77,6 M - -
Net income 2020 -161 M - -
Net cash 2020 262 M - -
P/E ratio 2020 -33,4x
Yield 2020 -
Capitalization 5 319 M 5 319 M -
EV / Sales 2019
EV / Sales 2020 65,2x
Nbr of Employees 237
Free-Float 86,6%
Chart ACCELERON PHARMA INC.
Duration : Period :
Acceleron Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACCELERON PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 116,31 $
Last Close Price 98,83 $
Spread / Highest target 38,6%
Spread / Average Target 17,7%
Spread / Lowest Target -27,1%
EPS Revisions
Managers
NameTitle
Habib J. Dable President, Chief Executive Officer & Director
Francois Nader Non-Executive Chairman
Christopher Rovaldi SVP-Program Management & Operations
Lisa Wyman Vice President-Operations
Kevin F. McLaughlin Chief Financial Officer, Treasurer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ACCELERON PHARMA INC.86.40%5 319
GILEAD SCIENCES19.78%97 628
VERTEX PHARMACEUTICALS31.52%74 661
REGENERON PHARMACEUTICALS63.21%62 233
WUXI APPTEC CO., LTD.15.61%24 620
GENMAB A/S39.05%20 072